A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer
Anthony W. Tolcher,David I. Quinn,Anna C. Ferrari,F. Ahmann,Giuseppe Giaccone,T. Drake,Anne Keating,J.S. de Bono +7 more
Reads0
Chats0
TLDR
YM155 has modest activity in taxane-pretreated CRPC with 25% of patients having prolonged stable disease (≥18 weeks) and the regimen appears to be well tolerated.About:
This article is published in Annals of Oncology.The article was published on 2012-04-01 and is currently open access. It has received 132 citations till now. The article focuses on the topics: Docetaxel & Progression-free survival.read more
Citations
More filters
Journal ArticleDOI
Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment
TL;DR: Some of the key regulatory molecules that control the apoptotic pathways, extrinsic and intrinsic death receptors, discuss how defects in apoptosis pathways contribute to cancer, and list several agents being developed to target apoptosis are introduced.
Journal ArticleDOI
Survivin at a glance
TL;DR: The structure, expression and function of survivin are described, its interactome is highlighted, and anti-survivin strategies are described being trialled, highlighting the current understanding of the structure, function and cancer implications of Survivin biology.
Journal ArticleDOI
Theranostics in nuclear medicine practice.
Anna Yordanova,Elisabeth Eppard,Stefan Kürpig,Ralph A. Bundschuh,Stefan Schönberger,Maria A. Gonzalez-Carmona,Georg Feldmann,Hojjat Ahmadzadehfar,Markus Essler +8 more
TL;DR: The aim of this review was to provide a summary of background knowledge and current applications, and to identify the advantages of targeted therapies and imaging in nuclear medicine practices.
Journal ArticleDOI
Cancer therapeutics: Targeting the apoptotic pathway
TL;DR: This review examines such treatment strategies, detailing the various compounds currently under clinical investigation, their potential roles in cancer therapeutics, and discussing approaches to their optimal use in the clinic.
Journal ArticleDOI
Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
TL;DR: The status of survivin cancer therapeutics is reviewed, and the current survivin mechanistic studies are summarized, with the goal of stimulating discussion that might facilitate translational research for discovering improved strategies and/or more effective anticancer agents that target survivin for cancer therapy.
References
More filters
Journal ArticleDOI
Optimal two-stage designs for phase II clinical trials.
TL;DR: Two-stage designs that are optimal in the sense that the expected sample size is minimized if the regimen has low activity subject to constraints upon the size of the type 1 and type 2 errors are presented.
Journal ArticleDOI
A novel anti-apoptosis gene, survivin , expressed in cancer and lymphoma
TL;DR: It is suggested that apoptosis inhibition may be a general feature of neoplasia and survivin is identified as a potential new target for apoptosis-based therapy in cancer and lymphoma.
Journal ArticleDOI
YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
Takahito Nakahara,Masahiro Takeuchi,Isao Kinoyama,Tsuyoshi Minematsu,Kenna Shirasuna,Akira Matsuhisa,Aya Kita,Fumiko Tominaga,Kentaro Yamanaka,Masafumi Kudoh,Masao Sasamata +10 more
TL;DR: These findings represent the first attempt to show tumor regression and suppression of survivin in p53-deficient human HRPC cells by a single small molecular compound treatment.
Journal ArticleDOI
Survivin mediates resistance to antiandrogen therapy in prostate cancer
TL;DR: The study indicates that upregulation of Survivin via IGF-1 signaling confers resistance to Flutamide in prostate cancer cells, supporting a novel mechanism of resistance to antiandrogen therapy.
Journal ArticleDOI
Survivin expression is associated with features of biologically aggressive prostate carcinoma.
Shahrokh F. Shariat,Shahrokh F. Shariat,Yair Lotan,M. Hossein Saboorian,Seyed M. Khoddami,Claus G. Roehrborn,Kevin M. Slawin,Raheela Ashfaq +7 more
TL;DR: The objectives of the current study were to compare the expression patterns of survivin in normal prostate, primary prostate carcinoma, and lymph node tissues involved with prostate cancer and to determine whether the expression of Survivin is associated with prostate carcinomas characteristics and progression.